中国生物技术2025年美国临床肿瘤学会（ASCO）摘要解读
摩根士丹利·2025-05-23 10:50
Surufatinib + KN046 in 1L PDAC - Better response and safety, with still-maturing mPFS competitive against SoC (link), albeit small samples (n=16, link). IBI363 +/- beva in MSS/pMMR CRC - Continues to demonstrate next-gen IO potential, with consistent ORR in larger samples (12.7%/23.5% +/- beva), and potential best-in-class mDoR of 7.5m/NR and mOS 16.1m/NR for monotherapy and combination therapy, respectively (link). See inside for peer data comparison. May 23, 2025 12:06 AM GMT China Healthcare | Asia Pacif ...